BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

LabConnect and OmniScience Partner to Launch Industry’s First AI Control Tower for Clinical Trial Lab Data

Together we're unlocking the true potential of clinical trial lab data, bringing faster insights, smarter decisions, and better outcomes. -- LabConn...

September 16, 2025 | News

BioAge Advances BGE-102 into Phase 1 Trials Triggering Milestone Payment to HitGen as DEL Technology Accelerates Drug Discovery

BGE-102, an orally available, brain-penetrant NLRP3 inhibitor, was developed from a hit compound identified using HitGen's industry-leading DEL technolog...

September 16, 2025 | News

Alphamab Oncology’s NDA for KN026 Accepted by NMPA for HER2-Positive Gastric Cancer

Alphamab Oncology announced that the New Drug Application (NDA) for anbenitamab injection (KN026), independently developed by the Company and co-developed ...

September 15, 2025 | News

Leads Biolabs Doses First Patient in Phase 1b/II Trial of Opamtistomig for Advanced Melanoma

Nanjing Leads Biolabs Co., announced the first patient has been successfully dosed in a Phase 1b/II clinical trial (NCT07099430) evaluating Opamt...

September 15, 2025 | News

Pulnovo Medical Secures Dual FDA IDE Approvals and CMS Coverage for PADN Clinical Trials in the U.S.

Pulnovo Medical, a globally recognized leader in medical devices for pulmonary hypertension (PH) and heart failure (HF), is proud to announce that its PADN...

September 15, 2025 | News

Mednovo Doses First Patient in Phase III Trial of Targeted Radiotherapeutic for GEP-NETs

Mednovo Group Co., Ltd. ("Mednovo") announced that the first patient has been successfully dosed in its Phase III clinical trial of Lutetium [177Lu] Oxodot...

September 12, 2025 | News

Kazia’s Paxalisib Disrupts Circulating Tumour Cell Clusters in HER2-Positive Metastatic Breast Cancer Study

Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced new findings from a collaborative research program...

September 12, 2025 | News

Zhimeng Biopharma Secures China’s Green Light for Phase 2 Trial of Next-Gen Epilepsy Drug CB03-154

Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma") announced that its self-developed novel next-generation KCNQ2/3 potassium channel opener, CB03-154, ...

September 12, 2025 | News

Telix Doses First Patient In Phase 3 BiPASS™ Trial Evaluating Illuccix® And Gozellix® For Prostate Cancer Diagnosis

Telix Pharmaceuticals Limited announces it has dosed the first patient in a Phase 3 clinical trial aimed at expanding the indications for Illuccix&re...

September 11, 2025 | News

Innorna completes Phase II enrollment for IN006, the first bivalent RSV mRNA vaccine

Innorna announced the completion of enrollment and vaccination in its Phase II clinical trial for IN006, the world’s first bivalent respiratory...

September 11, 2025 | News

XtalPi and PharmaEngine Advance AI-Designed PRMT5 Inhibitor PEP08 into Phase 1 Trials for Solid Tumours

XtalPi Inc. (Stock Code: 2228.HK) has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaborati...

September 10, 2025 | News

Takeda Wins U.S. FDA Approval to Expand VONVENDI Use in Adults and Children with Von Willebrand Disease

Approval Expands Use of VONVENDI to Include Routine Prophylaxis to Reduce the Frequency of Bleeding Episodes in Adults with Type 1 and 2 Von Willebrand D...

September 08, 2025 | Regulatory

AstraZeneca’s FLAURA2 Trial Confirms TAGRISSO Plus Chemotherapy Extends Survival in EGFR-Mutated Lung Cancer

FLAURA2 final overall survival analysis reinforces the favorable benefit-risk profile of this combination Results underscore TAGRISSO as 1st-line s...

September 08, 2025 | News

Taiwan’s Senhwa Biosciences Gains FDA IND Clearance for CX-5461 in MYC-Driven B-Cell Lymphomas

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company announced that the U.S. Food and Drug Administration (FDA) has gran...

September 08, 2025 | News

Stay Connected